D-dimers in omicron versus delta: A retrospective analysis

Southern African Journal of Infectious Diseases

 
 
Field Value
 
Title D-dimers in omicron versus delta: A retrospective analysis
 
Creator Shulman, Alon H. Jacobson, Barry Segal, Bradley M. Khan, Amber Trusler, Jessica Earlam, Lindsay Shemesh, Guy
 
Subject — SARS-CoV-2; D-dimer; B.1.1.529; B.1.617.2; omicron; delta
Description Background: Infection with SARS-CoV-2 has shown to cause an increase in D-dimers, which correlate with severity and prognosis for in-hospital mortality. The B.1.617.2 (delta) variant is known to cause a raised D-dimer level, with data on D-dimers in the B.1.1.529 (omicron) variant being scarce.Objectives: To determine the effect of age, gender and SARS-CoV-2 variant on the D-dimer in South Africans admitted to tertiary medical centres from May 2021 to December 2021.Method: The study was performed retrospectively on 16 010 adult patients with a SARS-CoV-2 infection. Age, gender, SARS-CoV-2 PCR and D-dimer levels on admission were collected from two national laboratories. Admissions from 01 May 2021 to 31 October 2021 were classified as B.1.617.2, whereas admissions from 01 November 2021 to 23 December 2021 were classified as B.1.1.529 infections.Results: Omicron infections had a median D-dimer level of 0.54 µg/mL (95% CI: 0.32, 1.08, p  0.001). Multivariable regression analysis showed that infection with omicron had a 34.30% (95% CI: 28.97, 39.23) reduction in D-dimer values, compared with delta infections. Middle aged, aged and aged over 80 years had D-dimer results greater than the adult baseline (42.6%, 95% CI: 38.0, 47.3, 124.6%, 95% CI: 116.0, 133.7 and 216.1%, 95% CI: 199.5, 233.3). Males on average had a 7.1% (95% CI: 4.6, 9.6) lower D-dimer level than females.Conclusion: Infection with the B.1.1.529 variant, compared with B.1.617.2 variant, had significantly lower D-dimer levels, with age being a more significant predictor of D-dimer levels, than gender and SARS-CoV-2 variant of infection.Contribution: This study provides novel insight into the hypercoagulable impact of various SARS-CoV-2 variants, which can guide the management of patients. 
 
Publisher AOSIS Publishing
 
Contributor Lancet Laboratories Ampath Laboratories
Date 2022-11-30
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Retrospective Review
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajid.v37i1.484
 
Source Southern African Journal of Infectious Diseases; Vol 37, No 1 (2022); 6 pages 2313-1810 2312-0053
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajid.co.za/index.php/sajid/article/view/484/1119 https://sajid.co.za/index.php/sajid/article/view/484/1120 https://sajid.co.za/index.php/sajid/article/view/484/1121 https://sajid.co.za/index.php/sajid/article/view/484/1122
 
Coverage — — —
Rights Copyright (c) 2022 Alon H. Shulman, Barry Jacobson, Bradley M. Segal, Amber Khan, Jessica Trusler, Lindsay Earlam, Guy Shemesh https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT